Literature DB >> 26067100

Assay strategies for identification of therapeutic leads that target protein trafficking.

P Michael Conn1, Timothy P Spicer2, Louis Scampavia2, Jo Ann Janovick3.   

Abstract

Receptors, enzymes, and ion channels are traditional targets of therapeutic development. A common strategy is to target these proteins with agents that either activate or suppress their activity with ligands or substrates that occupy orthosteric sites or have allosteric interactions. An alternative approach involves regulation of protein trafficking. In principle, this approach enables 'rescue' of misfolded and misrouted mutant proteins to restore function, 'shipwrecking' of undesirable proteins by targeting them for destruction, and regulation of levels of partially expressed wild type (WT) proteins at their functional sites of action. Here, we present drug discovery strategies that identify 'pharmacoperones', which are small molecules that serve as molecular templates and cause otherwise misfolded mutant proteins to fold and route correctly.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GPCR; mutant rescue; pharmacoperones; protein folding; protein mutants; protein trafficking

Mesh:

Substances:

Year:  2015        PMID: 26067100      PMCID: PMC4532603          DOI: 10.1016/j.tips.2015.05.004

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  82 in total

1.  Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy.

Authors:  V Heiser; E Scherzinger; A Boeddrich; E Nordhoff; R Lurz; N Schugardt; H Lehrach; E E Wanker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Freedom of expression. Focus on "Endoplasmic reticulum stress and the unfolded protein response regulate cystic fibrosis transmembrane conductance regulator expression".

Authors:  Neil A Bradbury
Journal:  Am J Physiol Cell Physiol       Date:  2006-09-27       Impact factor: 4.249

3.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

Authors:  Jonathan B Baell; Georgina A Holloway
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

4.  Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes.

Authors:  Umut Ozcan; Erkan Yilmaz; Lale Ozcan; Masato Furuhashi; Eric Vaillancourt; Ross O Smith; Cem Z Görgün; Gökhan S Hotamisligil
Journal:  Science       Date:  2006-08-25       Impact factor: 47.728

5.  Site-specific conformational studies of prion protein (PrP) amyloid fibrils revealed two cooperative folding domains within amyloid structure.

Authors:  Ying Sun; Leonid Breydo; Natallia Makarava; Qingyuan Yang; Olga V Bocharova; Ilia V Baskakov
Journal:  J Biol Chem       Date:  2007-01-23       Impact factor: 5.157

Review 6.  UPR activation alters chemosensitivity of tumor cells.

Authors:  Melissa J Mann; Linda M Hendershot
Journal:  Cancer Biol Ther       Date:  2006-07-01       Impact factor: 4.742

7.  Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target.

Authors:  Jo Ann Janovick; Guadalupe Maya-Nunez; P Michael Conn
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

8.  Pharmacological chaperones stabilize retromer to limit APP processing.

Authors:  Vincent J Mecozzi; Diego E Berman; Sabrina Simoes; Chris Vetanovetz; Mehraj R Awal; Vivek M Patel; Remy T Schneider; Gregory A Petsko; Dagmar Ringe; Scott A Small
Journal:  Nat Chem Biol       Date:  2014-04-20       Impact factor: 15.040

Review 9.  The mammalian unfolded protein response.

Authors:  Martin Schröder; Randal J Kaufman
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

10.  The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.

Authors:  Daniel R Carrasco; Kumar Sukhdeo; Marina Protopopova; Raktim Sinha; Miriam Enos; Daniel E Carrasco; Mei Zheng; Mala Mani; Joel Henderson; Geraldine S Pinkus; Nikhil Munshi; James Horner; Elena V Ivanova; Alexei Protopopov; Kenneth C Anderson; Giovanni Tonon; Ronald A DePinho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

View more
  7 in total

1.  Receptor antagonism/agonism can be uncoupled from pharmacoperone activity.

Authors:  Jo Ann Janovick; Timothy P Spicer; Emery Smith; Thomas D Bannister; Terry Kenakin; Louis Scampavia; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2016-07-04       Impact factor: 4.102

2.  Rescue of protein expression defects may not be enough to abolish the pro-arrhythmic phenotype of long QT type 2 mutations.

Authors:  Matthew D Perry; Chai Ann Ng; Kevin Phan; Erikka David; Kieran Steer; Mark J Hunter; Stefan A Mann; Mohammad Imtiaz; Adam P Hill; Ying Ke; Jamie I Vandenberg
Journal:  J Physiol       Date:  2016-05-27       Impact factor: 5.182

3.  Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.

Authors:  Justin T Marinko; Hui Huang; Wesley D Penn; John A Capra; Jonathan P Schlebach; Charles R Sanders
Journal:  Chem Rev       Date:  2019-01-04       Impact factor: 60.622

4.  Rescue of mutant gonadotropin-releasing hormone receptor function independent of cognate receptor activity.

Authors:  Emery Smith; Jo Ann Janovick; Thomas D Bannister; Justin Shumate; Vadivel Ganapathy; Louis Scampavia; Timothy P Spicer
Journal:  Sci Rep       Date:  2020-06-29       Impact factor: 4.379

5.  A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria.

Authors:  Helene J Bustad; Karen Toska; Caroline Schmitt; Marta Vorland; Lars Skjærven; Juha P Kallio; Sylvie Simonin; Philippe Letteron; Jarl Underhaug; Sverre Sandberg; Aurora Martinez
Journal:  Mol Ther       Date:  2019-12-04       Impact factor: 11.454

Review 6.  Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.

Authors:  Helene J Bustad; Juha P Kallio; Marta Vorland; Valeria Fiorentino; Sverre Sandberg; Caroline Schmitt; Aasne K Aarsand; Aurora Martinez
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

Review 7.  Epigenetic assays for chemical biology and drug discovery.

Authors:  Sheraz Gul
Journal:  Clin Epigenetics       Date:  2017-04-21       Impact factor: 6.551

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.